Skip to main content
Funded Studies

Rab Detection Initiative and LRRK2 Detection Initiative Supplemental Support RDI, and LCC exosome replication

This grant builds upon the research from a prior grant: Rab Detection Initiative

Study Rationale:
The LRRK2 detection initiative (LDI) and Rab detection initiative (RDI) are focused on developing techniques for the robust and sensitive detection of LRRK2, phospho-LRRK2, Rab and phospho-Rab in human biosamples to advance LRRK2 and Rabs as biomarkers of disease and of LRRK2 target engagement.

Hypothesis:
Measures of LRRK2 and phospho-LRRK2, as well as measures of the LRRK2 substrates of the Rab-GTPase family, are hypothesized to be linked to the development of Parkinson's disease (PD) and the inhibition of the LRRK2 kinase activity.

Study Design:
We will generate optimized LRRK2 recombinant protein standards and optimize sample processing procedures for urine and cerebrospinal fluid (clear liquid in the brain and spinal cord). We will also establish methods to detect Rab and phospho-Rab and apply these to human and pre-clinical models. If we are successful in detecting Rab in those sample types, we will test whether Rab or phospho-Rab are altered in individuals with PD and in pre-clinical models treated with LRRK2 kinase inhibitors.

Impact on Diagnosis/Treatment of Parkinson's disease:
LRRK2 and Rab proteins are strong candidate PD biomarkers and are biomarkers of pharmacodynamic response to LRRK2-targeting PD therapeutics.

Next Steps for Development:
If this project is successful, LRRK2 and Rab detection in biofluids will accelerate clinical trials and studies for PD therapeutics and ultimately be used as routine diagnostic tests for PD.


Researchers

  • Marie-Christine Chartier-Harlin, PhD

    Lille France


  • Jean-Marc Taymans, PhD/IR

    Lille France


Discover More Grants

Search by Related Keywords

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.